Appeal Ruling Forces NICE Rethink on Celgene’s Vidaza for MDS

Pharmatimes.com -- Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National Health Service.
MORE ON THIS TOPIC